Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
ATLANTA, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's executive team will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference being held at the Langham Hotel on Tuesday, December 15, 2015 in Boston, MA.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
CONTACT: Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3352
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
